meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
atezolizumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab
no study with result for this clinical condition